Alnylam Pharmace. buy William Blair
Start price
26.02.25
/
50%
€232.40
Target price
26.02.26
-
Performance (%)
20.96%
End price
27.02.26
€281.10
Summary
This prediction ended on 27.02.26 with a price of €281.10. The prediction had a final performance of 20.96%. William_Blair has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Alnylam Pharmace. | -5.145% | -5.145% | -5.076% |
| iShares Core DAX® | -2,68 % | 4,26 % | 2,12 % |
| iShares Nasdaq 100 | 0,73 % | 5,80 % | 34,20 % |
| iShares Nikkei 225® | -0,73 % | 9,32 % | 61,30 % |
| iShares S&P 500 | 1,17 % | 5,48 % | 24,75 % |
Comments by William_Blair for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at William Blair.
Ratings data for ALNY provided by MarketBeat
In the thread Trading Alnylam Pharmace.
Die von William_Blair gewählte maximale Laufzeit wurde überschritten